1. Search Result
Search Result
Results for "

SP

" in MedChemExpress (MCE) Product Catalog:

354

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

2

Biochemical Assay Reagents

40

Peptides

139

Natural
Products

49

Recombinant Proteins

7

Isotope-Labeled Compounds

12

Antibodies

1

Click Chemistry

40

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110182
    SP-141
    1 Publications Verification

    MDM-2/p53 Cancer
    SP-141 is a specific inhibitor of MDM2. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells .
    SP-141
  • HY-110177

    NF-κB Inflammation/Immunology
    SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA) .
    SP-100030
  • HY-131339
    SP-96
    1 Publications Verification

    Aurora Kinase Cancer
    SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI50=107 nM). SP-96 can be used for the research of triple negative breast cancer (TNBC) .
    SP-96
  • HY-16912

    Others Others
    SP-420 is a tridentate iron chelator belonging to the class of iron chelators, with oral activity. It is a derivative of desferrithiocin but has higher iron clearance efficiency and minimized renal toxicity compared to desferrithiocin, with an ICE (Iron Clearance Efficiency) value of 26.7. SP-420 can be used in research related to β-thalassemia .
    SP-420
  • HY-P2753

    SP

    Endogenous Metabolite Others Cancer
    Sucrose phosphorylase is a bacterial transglucosidase that catalyzes the conversion of sucrose and phosphate into α-D-glucose-1-phosphate and D-fructose. The glucosylated Sucrose phosphorylase can also be hydrolyzed into α-D-glucose, or transfer the glucoyl to the hydroxyl group of the receptor, and then decomposed into new α-D-glucoside products. The enzymatic activity of base phosphorylase to substrate and product is weak .
    Sucrose phosphorylase
  • HY-144647

    SARS-CoV Virus Protease Infection
    SP inhibitor 1 (compound 34) is a selective SARS-CoV-2 spike protein (SP) inhibitor with an IC50 of 3.26 μM, >25 μM, >25 μM for SP, M pro and PL pro protein, respectively. SP inhibitor 1 is a vitro SARS-CoV-2 replication inhibitor at non-toxic concentrations (0.3250<5.98 μM). SP inhibitor 1 shows cellular antiviral activity .
    SP inhibitor 1
  • HY-144646

    Flavivirus Dengue virus Virus Protease Infection
    SP-471 is a potent dengue virus (DENV) protease inhibitor with IC50 value of 18 μM. SP-471 inhibits both intermolecular and intramolecular protease processes of DENV .
    SP-471
  • HY-P3258

    Cholinesterase (ChE) Infection
    SP-10 is a small peptide derived from S protein with an IC50 value of 1.88 nM for blocks the interaction between S protein and ACE2. SP-10 can be used for SARS-CoV research .
    SP-10
  • HY-155176

    HDAC Cancer
    SP-2-225 is a selective HDAC6 inhibitor. SP-2-225 enhance the production of cancer-associated antigens and macrophage antigen cross-presentation to T cells. SP-2-225 reduces the tumor volume in a syngeneic SM1 melanoma model .
    SP-2-225
  • HY-137614

    Biochemical Assay Reagents Others
    Sp-GTPαS is a phosphonothioate analog of GTP. Sp-GTPαS is more metabolically stable than GTP .
    Sp-GTPαS
  • HY-137632

    Others Cancer
    Sp-8-Cl-cAMPS is an analog of cAMP (HY-B1511) and a derivative of Sp-8-Cl-cAMP. Sp-8-Cl-cAMPS inhibits the growth of human leukemia cell HL-60 and colon cancer cell LS-174T, with IC50 of 8-100 μM. Sp-8-Cl-cAMPS activates the protein kinases cAKI and cAKII, with Ka of 0.25 and 3.2 μM .
    Sp-8-Cl-cAMPS
  • HY-137639

    HCN Channel Neurological Disease
    Sp-8-Br-cGMPS is an analog of cGMP. Sp-8-Br-cGMPS is an agonist for cGMP-gated cation channels (CNG channels), with an EC50 of 106.5 μM. Sp-8-Br-cGMPS induces the currents, without the ability to stabilize the channel open state as a full agonist .
    Sp-8-Br-cGMPS
  • HY-137615

    Biochemical Assay Reagents Others
    Sp-GDPαS is a regulator of GDP-binding proteins. Sp-GDPαS is metabolically more stable than GTP .
    Sp-GDPαS
  • HY-137618

    Biochemical Assay Reagents Others
    Sp-dGDPαS is a regulator of GDP-binding proteins. Sp-dGDPαS is metabolically more stable than GTP .
    Sp-dGTPαS
  • HY-137619

    Biochemical Assay Reagents Others
    Sp-dCTPαS is a regulator of CTP-binding proteins. Sp-dCTPαS is metabolically more stable than CTP .
    Sp-dCTPαS
  • HY-137620

    Biochemical Assay Reagents Others
    Sp-dADPαS is a regulator of ADP-binding proteins. Sp-dADPαS is metabolically more stable than ATP .
    Sp-dATPαS
  • HY-137626

    Biochemical Assay Reagents Others
    Sp-ATPαS is a regulator of ATP-binding proteins. Sp-ATPαS is metabolically more stable than ATP .
    Sp-ATPαS
  • HY-137627

    Biochemical Assay Reagents Others
    Sp-ADPαS is a regulator of ADP-binding proteins. Sp-ADPαS is metabolically more stable than ADP .
    Sp-ADPαS
  • HY-137638A

    SP-5,6-DCI-cBIMPS

    PKA Metabolic Disease
    Sp-5,6-DCl-cBIMPS sodium is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS sodium stimulates insulin release. Sp-5,6-DCl-cBIMPS sodium inhibits U-46619 (HY-108566)-induced activation of Rho, Gq and G12/G13 in platelets .
    Sp-5,6-DCl-cBIMPS sodium
  • HY-161794

    FKBP Ligands for Target Protein for PROTAC Cancer
    SP3N is a specific degrader of the prolyl isomerase FKBP12. The alkylamine of SP3N is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCFFBXO22 ligase for FKBP12 degradation. SP3N may be used in research for cancer .
    SP3N
  • HY-137622

    PKG Cardiovascular Disease
    Sp-cGMPS is an activator of cGMP-dependent protein kinases (PKGs). Sp-cGMPS can be used in cardiovascular disease-related research .
    Sp-cGMPS
  • HY-137635

    PKA Neurological Disease
    Sp-6-Phe-cAMPS is a potent, site-selective and membrane-permeable activator of cAMP-dependent protein kinase. Sp-6-Phe-cAMPS does not activate exchange factors directly activated by cAMP and can therefore be used as an Epac negative control. Sp-6-Phe-cAMPS can be used in the study of neurodegenerative diseases .
    Sp-6-Phe-cAMPS
  • HY-137640

    PKA Others
    Sp-8-Br-cAMPS is an analog of cAMP(HY-B1511). Sp-8-Br-cAMPS is an agonist for cAMP, which performs a protein kinase A (PKA) activating activity with EC50 of 360 nM. Sp-8-Br-cAMPS inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .
    Sp-8-Br-cAMPS
  • HY-137646

    PKA Parasite Infection
    Sp-2-Cl-cAMPS is an agonist for PKA with improved membrane permeability and stability to phosphodiesterase. Sp-2-Cl-cAMPS exhibits antimalarial activity, and inhibits the proliferation of Plasmodium falciparum with an EC50 of 4 μM. Sp-2-Cl-cAMPS binds to purified P. falciparum PfPKAr (regulatory subunit of PfPKA) with a Ki of 1.3 µM .
    Sp-2-Cl-cAMPS
  • HY-137624

    PKA Others
    Sp-cAMPS-AM is an analog of cAMP. Sp-cAMPS-AM acts as the inducer of PKA activation and CREB phosphorylation, through entrance into the cell and release of its parent polar structure Sp-cAMPS .
    Sp-cAMPS-AM
  • HY-161795

    Others Cancer
    SP3CHO is an active metabolite generated by the metabolism of SP3N in cell culture by the action of amine oxidase. SP3CHO can induce polyubiquitination of specific proteins by recruiting the SCFFBXO22 E3 ligase complex. SP3CHO can be used in cancer therapy research .
    SP3CHO
  • HY-149324

    PROTACs Polo-like Kinase (PLK) Cancer
    SP27 is a PROTAC that can selective degrades PLK4, with a DC50 of 19.5 nM. SP27 can be used for the research of breast cancer .
    SP27
  • HY-100530B

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS
  • HY-100530C

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS sodium salt
  • HY-12041
    SP600125
    Maximum Cited Publications
    444 Publications Verification

    JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125
  • HY-137640A

    PKA Inflammation/Immunology
    Sp-8-Br-cAMPS sodium is a cAMP analog, which performs a protein kinase A (PKA) activating activity with EC50 of 360 nM. Sp-8-Br-cAMPS sodium inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .
    Sp-8-Br-cAMPS sodium
  • HY-137633

    PKG Neurological Disease
    Sp-8-Br-PET-cGMPS is a membrane-permeable PKG agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system .
    Sp-8-Br-PET-cGMPS
  • HY-137629

    PKG Cardiovascular Disease
    Sp-8-pCPT-PET-cGMPS is an activator for PKG-I. Sp-8-pCPT-PET-cGMPS can be used for research of NO/NOS/sGC/PKG-I signaling pathway in cardiac differentiation .
    Sp-8-pCPT-PET-cGMPS
  • HY-137638

    PKA Metabolic Disease
    Sp-5,6-DCl-cBIMPS is a potent and specific cAMP-dependent protein kinases (cAMP-PK) activator. Sp-5,6-DCl-cBIMPS stimulates insulin release. Sp-5,6-DCl-cBIMPS inhibits U46619-induced activation of Rho, Gq and G12/G13 in platelets .
    Sp-5,6-DCl-cBIMPS
  • HY-137613

    HIV Infection Inflammation/Immunology
    Sp-TTPαS is a competitivesterile alpha motif and HD domain containing protein 1 (SAMHD1) catalysis inhibitor. Sp-TTPαS competitively inhibits TTP hydrolysis with a Ki value of 46 µM .
    Sp-TTPαS
  • HY-144645

    Flavivirus Dengue virus Virus Protease DNA/RNA Synthesis Infection
    SP-471P is a potent dengue virus (DENV) protease inhibitor with EC50s of 5.9 μM, 1.4 μM, 5.1 μM and 1.7 μM for DENV1, DENV2, DENV3 and DENV4, respectively and CC50 value over 100 μM. SP-471P can reduce DENV viral RNA synthesis .
    SP-471P
  • HY-P5569

    Fungal Infection
    SP-B peptide is an antimicrobial peptide. SP-B peptide has antifungal activity against strains of Cryptococcus neoformans, Candida albicans and Aspergillus fumigatus
    SP-B peptide
  • HY-137628

    PKA Cancer
    Sp-8-PIP cAMP sodium is a non-corresponding isomer of 8-Piperidino-cAMP. 8-Piperidino-cAMP binds with high affinity to site A of the regulatory subunit of cAMP-dependent protein kinase type I (AI). Sp-8-PIP cAMP sodium can be used as an antagonist of cAMP-induced activation .
    Sp-8-PIP cAMP
  • HY-160991

    SP-204

    Phosphodiesterase (PDE) Others Neurological Disease
    Menabitan (SP-204) is an inhibitor for phosphodiesterase 9 (PDE 9), which acts as a non-opioid analgesic agent. Menabitan lowers the intraocular pressure in rabbit model .
    Menabitan
  • HY-110005

    PKA Phosphodiesterase (PDE) Neurological Disease Metabolic Disease
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM .
    Sp-cAMPS triethylamine
  • HY-120994B

    PKA Neurological Disease Inflammation/Immunology
    Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .
    Sp-8-CPT-cAMPS
  • HY-137623

    Biochemical Assay Reagents Others
    Sp-cCMPS is a cCMP analog that activates the binding protein of cCMP .
    Sp-cCMPS
  • HY-137641

    Ras Metabolic Disease
    Sp-8-Br-2'-O-Me-cAMPS is a cAMP analog. Sp-8-Br-2'-O-Me-cAMPS is an activator of EPAC. Sp-8-Br-2'-O-Me-cAMPS can be used in metabolism-related studies .
    Sp-8-Br-2'-O-Me-cAMPS
  • HY-137108

    PKA PKG Neurological Disease
    Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .
    Sp-8-pCPT-cGMPS
  • HY-160991A

    SP-204 dihydrochloride

    Phosphodiesterase (PDE) Others Neurological Disease
    Menabitan dihydrochloride (SP-204 dihydrochloride) is the dihydrochloride form of Menabitan (HY-160991). Menabitan dihydrochloride is an inhibitor for phosphodiesterase 9 (PDE 9), which acts as a non-opioid analgesic agent. Menabitan dihydrochloride lowers the intraocular pressure in rabbit model .
    Menabitan dihydrochloride
  • HY-137630

    Ras Metabolic Disease
    Sp-8-pCPT-2'-O-Me-cAMPS is an activator of EPAC. Sp-8-pCPT-2'-O-Me-cAMPS can be used in endocrine metabolism related research .
    Sp-8-pCPT-2'-O-Me-cAMPS
  • HY-156276

    PPAR Metabolic Disease
    SP4e is an activator of PPAR-γ, with the EC50 of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4e
  • HY-156277

    PPAR Metabolic Disease
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4f
  • HY-119424

    Interleukin Related Inflammation/Immunology
    SP4206 is an IL-2/IL-2Rα interaction inhibitor. SP4206 binds with high affinity (Kd=70 nM) to IL-2 and blocks binding to its natural receptor IL-2Rα (Kd=10 nM) .
    SP4206
  • HY-12635
    SP2509
    5+ Cited Publications

    Histone Demethylase Apoptosis Cancer
    SP2509 is a potent and selective antagonist of lysine specific demethylase 1 (LSD1) with an IC50 of 13 nM .
    SP2509

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: